Oleh Nabyt
About Oleh Nabyt
Oleh Nabyt is an independent director of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), appointed in February 2025, age 31. He holds a bachelor’s degree from Rutgers University (2016) and brings FP&A and process improvement experience from roles at Zoetis, Hudson Group, and NCLH; he serves on SHPH’s Audit, Compensation, and Nominating & Corporate Governance (NCG) committees as a member. He is classified as independent under Nasdaq Rule 5605(a)(2).
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Zoetis | Financial Analyst | Jun 2017 – Sep 2018 | Led data governance, KPI dashboards, and process streamlining during a growth phase |
| Hudson Group | Lead Financial Associate (FP&A) | Sep 2018 – Apr 2020 | Worked under CFO; close collaboration with Investor Relations |
| NCLH | Finance Manager | May 2021 – present | Oversees ~$500M budget; increasing financial management responsibilities |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| — | — | — | No other public company directorships disclosed |
Board Governance
- Independence: Independent director under Nasdaq Rule 5605(a)(2).
- Committee assignments (current): Audit (member), Compensation (member), NCG (member).
- Committee chairs (context): Audit chair—Steve Richards; Compensation chair—George Scorsis; NCG chair—Joseph Tung.
- Lead Independent Director: None designated; independent directors hold executive sessions collaboratively (at least annually).
- Board activity (2024): 5 board meetings; 8 actions by written consent; 100% attendance by directors in 2024 (note: Nabyt joined in 2025; his 2025 attendance not disclosed in the proxy).
- Cybersecurity oversight: Board administers cybersecurity risk oversight and established a two-member Cybersecurity Committee (both independent).
2025 Shareholder Vote Outcomes (Context)
| Item | For | Against | Abstain/Withheld | Broker Non-Votes |
|---|---|---|---|---|
| Election of director – Oleh Nabyt | 2,428,743 | — | 670,874 | 1,078,407 |
| Say-on-Pay (advisory) | 2,542,575 | 469,312 | 87,730 | 1,078,407 |
| Reverse Stock Split authorization | 3,090,168 | 864,467 | 223,389 | — |
| 2018 Plan share reserve increase (+5,000,000) | 2,522,161 | 492,378 | 85,078 | 1,078,407 |
Fixed Compensation (Director)
| Component | Amount | Terms |
|---|---|---|
| Annual cash retainer | $25,000 | Payable quarterly |
| Committee membership fees | N/A | Not disclosed |
| Committee chair fees | N/A | Not applicable (not a chair) |
| Meeting fees | N/A | Not disclosed |
| Expense reimbursement | Actuals | Out-of-pocket meeting expenses reimbursed |
Performance Compensation (Director)
| Equity Vehicle | Grant Value | Vesting | Performance Metrics |
|---|---|---|---|
| RSUs (initial appointment) | $100,000 | Vests 1/3 on each of the first three anniversaries following appointment | None disclosed; time-based vesting |
- Additional annual RSU awards may be determined by the board.
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public company boards | None disclosed |
| Prior public company boards | None disclosed |
| Interlocks with SHPH competitors/suppliers/customers | None disclosed |
Expertise & Qualifications
- Education: Bachelor’s degree, Rutgers University, 2016.
- Technical/functional expertise: Financial analysis, data governance, KPI dashboarding, FP&A, and large-budget oversight (~$500M at NCLH).
- Board skills relevance: Finance/FP&A skillset supports Audit and Compensation committee responsibilities.
Equity Ownership
| Metric | Value | Notes |
|---|---|---|
| Common stock beneficially owned (#) | “-” (<1%) | As of record date March 13, 2025, individual line shows “-” (less than 1%) |
| Ownership % | <1% | Footnote denotes “-” = less than 1% |
| Unvested RSUs | 184,162 | Not included in beneficial ownership; unvested |
| Options outstanding | None disclosed | — |
| Shares pledged | None disclosed | — |
| Shares outstanding (context) | 6,257,693 | As of March 13, 2025 record date |
| Ownership guidelines | Not disclosed | No director stock ownership guideline disclosed |
Governance Assessment
- Board effectiveness and engagement: Nabyt is independent and serves on all three key committees (Audit, Compensation, NCG), aligning his finance background with oversight roles; board held 5 meetings in 2024 with 100% attendance (Nabyt joined in 2025; his attendance for 2025 not yet disclosed in proxy).
- Compensation and alignment: Standardized non-employee director pay—$25,000 cash retainer plus $100,000 time-vested RSUs on appointment; no disclosed committee or meeting fees; no performance metrics tied to director equity; unvested RSUs of 184,162 suggest equity alignment grows over time.
- Independence and conflicts: He is independent and no related-party transactions involving Nabyt are disclosed; insider trading policy with blackout periods is in place; company adopted a clawback policy for Section 16 officers and employees tied to restatements (policy scope does not expressly include directors).
- Shareholder sentiment and capital structure context: His election received 2,428,743 votes for with 670,874 withheld; say-on-pay passed (2,542,575 for vs. 469,312 against); shareholders also approved a significant increase to the equity plan (+5,000,000 shares) and authorized a reverse split—governance environment is capital-markets focused.
- Risk indicators and red flags:
- No lead independent director designated; independent directors hold executive sessions at least annually.
- Board turnover in 2025 (e.g., post-AGM resignation of Anatoly Dritschilo from CSO and director roles; later resignation of director Steve Richards), elevating governance transition risk.
- Significant potential dilution approved via plan share increase and reverse-split authority; additional financing proposals pursued in supplemental proxy, highlighting ongoing capital needs.
Overall: Nabyt brings modern FP&A and process rigor and is positioned across all three core committees, supporting board oversight. Equity alignment is primarily time-based RSUs, with no performance conditions disclosed. No conflicts involving Nabyt are disclosed; however, the broader board context includes leadership changes and capital actions that investors should monitor.